Pro-dopaminergic pharmacological interventions for anhedonia in depression: protocol for a living systematic review of human and non-human studies.

Journal: Wellcome open research

Volume: 8

Issue: 

Year of Publication: 

Affiliated Institutions:  Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UK. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK. Department of Psychiatry, University of Oxford, Oxford, England, UK. Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany. EPPI Centre, Social Research Institute, University College London, London, England, UK. Department of Psychiatry, Stellenbosch University, Stellenbosch, Western Cape, South Africa. MQ Mental Health Research, London, UK. Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, ISCIII, School of Medicine, Universidad Complutense de Madrid, Madrid, Community of Madrid, Spain. Department of Health Promotion and Human Behavior / School of Public Health, Kyoto University, Kyoto, Kyoto Prefecture, Japan.

Abstract summary 

Anhedonia is a key symptom of depression, and it has been suggested as a potential target for future individualised treatments. However, much is unknown about how interventions enhancing dopaminergic pathways may affect anhedonia symptoms in the context of depression. We will perform independent searches in multiple electronic databases to identify clinical and animal experimental studies on pro-dopaminergic interventions in individuals with depression or animal models for depression. The primary outcomes will be overall anhedonia symptoms and their behavioural proxies in animals. Secondary outcomes will include side effects and neurobiological measures. At least two independent reviewers will conduct the study selection, data extraction, and risk of bias assessments using pre-defined tools according to each record's study design. We will develop ontologies to facilitate study identification and data extraction. We will synthesise data from clinical and animal studies separately. If appropriate, we will use random-effects meta-analyses, or synthesis without meta-analyses. We will investigate study characteristics as potential sources of heterogeneity. We will evaluate the confidence in the evidence for each outcome and source of evidence, considering the summary of the association, potential concerns regarding internal and external validity, and reporting biases. When multiple sources of evidence are available for an outcome, we will draw an overall conclusion in a triangulation meeting involving a multidisciplinary team of experts. We plan updates of the review every 6 months, and any future modifications to the protocol will be documented. We will co-produce this review with multiple stakeholders. CRD42023451821.

Authors & Co-authors:  Ostinelli Edoardo G EG Chiocchia Virginia V Macleod Malcolm M Browning Michael M Harmer Catherine C Siafis Spyridon S Stansfield Claire C Friedrich Claire C Wright Simonne S Chikaura Tanatswa T Milligan Lea L Thomas James J Moreno Carmen C Furukawa Toshi A TA Seedat Soraya S Potts Jennifer J Salanti Georgia G Cipriani Andrea A

Study Outcome 

Source Link: Visit source

Statistics
Citations :  American Psychological Association: Diagnostic and statistical manual of mental disorders, 5th edition.American Psychological Association, Washington, DC (APA 2013),2015. Reference Source
Authors :  19
Identifiers
Doi : 425
SSN : 2398-502X
Study Population
Male,Female
Mesh Terms
Other Terms
GALENOS; dopamine; neurotransmitters; anhedonia; depression.
Study Design
Study Approach
Systemic Review
Country of Study
Publication Country
England